Confirmation of receipt of £860k R&D tax credits
Renalytix plc confirmed the receipt of £860k in Research and Development Tax Credits related to work completed in the fiscal years ending June 30, 2023, and June 30, 2024. The company received £296k during Q1 FY26, adding to the £564k received in Q4 FY25. Renalytix anticipates receiving an additional credit in early Q3 FY26 for work completed in FY25.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 27 October 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, confirms the receipt of Research and Development Tax Credits totalling £860k in relation to work completed in the fiscal years ended 30 June 2023 and 30 June 2024.
The Company received a payment of £296k in Q1 FY26, adding to the £564k payment received in Q4 FY25.
The Company expects a further credit to be received in early Q3 FY26 in relation to work completed in FY25.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.